Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel.
BACKGROUND The management of metastatic castration-resistant prostate cancer (mCRPC) after progression on androgen receptor pathway inhibitors (ARPI) and docetaxel presents a critical therapeutic choice between cabazitaxel and [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT). This review provides a comprehensive analy...